Development and Validation of RP-Chiral HPLC Method for Determination of (R)-Enantiomer Excess Content in Efavirenz
暂无分享,去创建一个
[1] N. Mazumder,et al. Enantiomeric Recognition and Separation by Chiral Nanoparticles , 2019, Molecules.
[2] G. Meintjes. Efavirenz , 2018, Reactions Weekly.
[3] A. Nag. Asymmetric Synthesis of Drugs and Natural Products , 2018 .
[4] O. Coskun. Separation techniques: Chromatography , 2016, Northern clinics of Istanbul.
[5] R. Silvestri,et al. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors , 2016, Molecules.
[6] N. Boechat,et al. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. , 2016, European journal of medicinal chemistry.
[7] I. Truter,et al. Efavirenz : a review of the epidemiology, severity and management of neuropsychiatric side-effects , 2015 .
[8] F. Maggiolo. Efavirenz: a decade of clinical experience in the treatment of HIV , 2009, The Journal of antimicrobial chemotherapy.
[9] Silas W Smith. Chiral toxicology: it's the same thing...only different. , 2009, Toxicological Sciences.
[10] B. Best,et al. Efavirenz – Still First-line King? , 2008, Expert opinion on drug metabolism & toxicology.
[11] F. Wit,et al. Efavirenz: a review , 2007, Expert opinion on pharmacotherapy.
[12] Sarah K Branch,et al. Guidelines from the International Conference on Harmonisation (ICH). , 2005, Journal of pharmaceutical and biomedical analysis.
[13] D. Thiébaut,et al. Evaluation of a ristocetin bonded stationary phase for subcritical fluid chromatography of enantiomers. , 2003, Chirality.
[14] R. C. Williams,et al. Column selection and method development for the determination of the enantiomeric purity of investigational non-nucleoside reverse transcriptase inhibitors. , 2001, Chirality.
[15] K. Groen,et al. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. , 1994, Chirality.